HAMILTON, BERMUDA, April 15, 2025 - DHT Holdings, Inc. ( NYSE:DHT ) ( "DHT" or the "Company" ) today announces that it has entered into an agreement to sell the DHT Lotus and the DHT Peony for a combined price of $103 million. Both vessels were built at Bohai Shipbuilding Heavy Industry Co, ...

Nimacimab shows comparable weight loss to monlunabant and tirzepatide alone, and an additive effect in combination with tirzepatide, in diet-induced obesity model New in vitro data demonstrates superior potency of nimacimab's differentiated and favorable mechanism of inhibition versus monlunabant

TREZZO SULL'ADDA, Italy, April 15, 2025 ( GLOBE NEWSWIRE ) -- GXO Logistics, Inc. ( NYSE: GXO ) , the world's largest pure-play contract logistics provider, announced today the signing of an agreement with PRG Retail Group, one of the main retailers of children's items and toys, to serve as its ...

New clinical data from the SYMON-I study to evaluate IL-6 in sepsis patients to be presented. New clinical data from the SYMON-I study to evaluate IL-6 in sepsis patients to be presented.

ACTON, Mass., April 15, 2025 ( GLOBE NEWSWIRE ) -- Bluejay Diagnostics, Inc. BJDX, today announced acceptance of an abstract related to the Symphony IL-6 Test, the company's lead product candidate, for presentation at the Society of Academic Emergency Medicine ( SAEM ) Annual Meeting, taking ...

VANCOUVER, British Columbia, April 15, 2025 ( GLOBE NEWSWIRE ) -- HydroGraph Clean Power Inc. ( CSE: ‎HG ) ( OTCQB: HGCPF ) ( the "Company" or "HydroGraph" ) a sustainable commercial manufacturer of pristine graphene, ( the "Company" ) is pleased to announce that President & CEO Kjirstin Breure ...

-Fresh from a $50M round of investment, Unframe is now eyeing North America and ...

Memphis, TN April 15, 2025 -- ( PR.com ) -- Meridian Pacific Properties is excited to announce the launch of The Investor Exploration Program, a unique opportunity for investors to visit Memphis, tour high-quality investment properties, and experience firsthand the benefits of owning turnkey ...

WATERTOWN, Mass., April 15, 2025 ( GLOBE NEWSWIRE ) -- Remix Therapeutics ( Remix ) , a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced the appointment of life science executive, ...

Company to share new preclinical combination data for FHD-909 ( LY4050784 ) , a potential first-in-class selective SMARCA2 inhibitor, with non-small cell lung cancer ( NSCLC ) as the primary target population ...